查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1835494

男性不孕症市场（按治疗类型、产品类型、最终用户和分销管道）—2025-2032 年全球预测

Male Infertility Market by Treatment Type, Product Type, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，男性不孕症市场规模将成长至 83.3 亿美元，复合年增长率为 9.30%。

主要市场统计数据
基准年2024年 40.9亿美元
预计2025年 44.6亿美元
预测年份：2032年 83.3亿美元
复合年增长率（%） 9.30%

全面介绍影响男性不孕症治疗的临床、技术和政策方面以及多种治疗环境下的行业反应

男性不孕症已从一个小众临床问题演变为生殖医学、诊断学、器材工程和公共卫生政策交叉领域的多学科挑战。随着检测技术的进步、对遗传和内分泌因素的深入了解以及患者认知度的提高，男性不孕症已成为不孕症治疗的核心问题。随着临床医生和研究人员不断完善诊断标准和治疗方法，产业相关人员正在重新调整其产品组合，以兼顾紧急临床需求和长期生殖健康结果。

与传统的治疗视角不同，现代实践强调整合医学，将精准诊断与个人化治疗方案结合。辅助生殖技术的普及，以及对精液分析、基因检测和微创手术技术的投资，正在为跨临床学科和商业领域的合作创造机会。在这一转变中，法律规范和付款方考量持续影响技术的采用和临床试验的设计，凸显了创新者、临床医生和政策制定者之间策略合作的必要性。

技术进步、以患者为中心的护理模式以及诊断主导的途径如何重塑男性不孕症的临床实践和商业策略

由于技术的日趋成熟、患者期望的不断变化以及诊断和治疗手段的融合，男性不孕症治疗领域正在发生变化。精准诊断，例如更便捷的基因检测和高解析度精液分析，正在重新定义诊断途径，并促成个人化介入。同时，辅助生殖技术的不断改进，例如卵细胞质内单一精虫显微注射术和靶向精子提取，正在为存在显着男性因素问题的夫妇提供更多治疗选择。

同时，非传统治疗方法正日益普及。生活方式疗法和替代疗法，例如针灸、营养优化和系统性体重管理，正日益被纳入孕前护理计划。这种转变反映了更广泛的卫生系统优先事项，即更倾向于整体的、以患者为中心的模式和预防策略。在商业方面，设备的小型化、实验室自动化程度的提高以及远端监控数位化工具的采用，正在降低服务扩展的门槛，并鼓励新进入者和策略合作伙伴关係的建立。总而言之，这些动态正在重塑临床决策，并加速研究成果转化为实践。

评估 2025 年实施的美国关税对生殖健康设备、诊断和治疗分销的累积营运和供应链影响

2025年美国关税的推出和实施，为支持生殖健康技术的全球供应链带来了显着的摩擦，对製造商、经销商和临床服务提供者产生了影响。离心机、培养箱和精密显微镜等专用设备的进口成本增加，增加了实验室和诊所的采购复杂性，促使一些医疗保健提供者重新评估其供应商关係和库存策略。为此，製造商和经销商探索了本地组装、采购多元化和价格调整等方案，以维持对必需设备的供应。

除了设备之外，关税还可能影响用于基因检测、荷尔蒙测定和精液分析的诊断耗材和试剂的供应和成本结构。这些压力促使实验室网路优化采购週期，投资于替代供应商的技术检验，并加速采用更有效率的工作流程，以减少每次检测的耗材使用量。同时，跨境生物製药和补​​充剂正面临经济转型，这可能会影响其销售管道策略，一些供应商优先考虑直销和区域合作，以减轻关税的影响。因此，相关人员正在平衡短期营运应对措施和长期策略倡议，以增强对持续贸易政策波动的抵御能力。

以细分市场为重点的洞察，将治疗方法、产品类型、临床最终用户和分销策略联繫起来，以确定开发和商业化路径的优先顺序

男性不孕症领域细分领域的动态揭示了差异化的价值驱动因素，这些因素为跨治疗方式、产品类型、最终用户和通路的产品开发和市场加速策略提供了资讯。辅助生殖技术包括ICSI、IUI和IVF；生活方式和替代疗法包括针灸、营养补充和体重管理；药物疗法包括抗生素疗法、抗氧化疗法和荷尔蒙疗法；手术疗法包括睪丸精子提取、精索静脉曲张切除术和血管成形术。每个治疗领域都呈现不同的临床工作流程、报销考量和证据生成需求，这些都会影响采用时间表。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 针对Y染色体微缺失的基因治疗进展，以优化男性生育能力
  • 氧化压力生物标记研究的激增将指导男性不孕症治疗中的个人化抗氧化疗法。
  • 男科学研究所扩大人工智慧精液分析平台的应用，以提高诊断准确性
  • 扩大以远端医疗基础的不孕症咨询服务，以解决男性获得生殖保健服务的差异
  • 发展 3D 睪丸类器官作为男性不孕症研究中新药筛检的预测模型
  • 增加对非荷尔蒙男性避孕药的投资将影响睪丸调节研究

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章 男性不孕症市场（依治疗类型）

  • 辅助生殖技术
    • 卵胞浆内单一精子注射
    • 人工授精
    • 体外受精
  • 生活方式和替代疗法
    • 针刺
    • 营养补充
    • 体重管理
  • 药物治疗
    • 抗生素治疗
    • 抗氧化疗法
    • 荷尔蒙疗法
  • 外科手术
    • 睪丸精子采集
    • 静脉曲张切除术
    • 血管吻合术

9. 男性不孕症市场（依产品类型）

  • 装置
    • 离心机
    • 培养箱
    • 显微镜
  • 诊断
    • 基因检测
    • 荷尔蒙水平测试
    • 精液分析
  • 药物
    • 抗生素
    • 抗氧化剂
    • 荷尔蒙
  • 补充
    • 胺基酸
    • 草本萃取物
    • 维他命

第 10 章 男性不孕症市场（依最终使用者）

  • 诊断中心
  • 不孕不育诊所
  • 医院
  • 研究机构

第十一章 男性不孕市场（依分销管道）

  • 直销
  • 医院药房
  • 网路药局
  • 零售药局

第十二章 男性不孕市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 男性不孕市场（依群体）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 男性不孕市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Ferring Arzneimittel AG
    • Merck KGaA
    • Bayer AG
    • Sun Pharmaceutical Industries Ltd
    • Endo International plc
    • Roche Diagnostics International AG
    • Thermo Fisher Scientific Inc
    • Cook Medical LLC
    • Hamilton Thorne Ltd
    • Vitrolife AB
Product Code: MRR-43286DA08074

The Male Infertility Market is projected to grow by USD 8.33 billion at a CAGR of 9.30% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.09 billion
Estimated Year [2025] USD 4.46 billion
Forecast Year [2032] USD 8.33 billion
CAGR (%) 9.30%

A comprehensive introduction to the evolving clinical, technological, and policy dimensions shaping male infertility care and industry response across multiple care settings

Male infertility has evolved from a niche clinical concern into a multidisciplinary challenge that intersects reproductive medicine, diagnostics, device engineering, and public health policy. Advances in laboratory techniques, a deeper understanding of genetic and endocrine contributors, and growing patient awareness have elevated male factor infertility to a central consideration in fertility pathways. As clinicians and researchers refine diagnostic criteria and therapeutic approaches, industry stakeholders are recalibrating portfolios to address both acute clinical needs and long-term reproductive health outcomes.

Transitioning from historical perspectives, contemporary practice emphasizes integrated care that combines precision diagnostics with individualized treatment plans. The surge in assisted reproductive technologies has been paralleled by investments in semen analytics, genetic testing, and minimally invasive surgical techniques, creating opportunities for collaboration across clinical disciplines and commercial segments. Amid these shifts, regulatory frameworks and payer considerations continue to influence technology adoption and clinical trial design, underscoring the need for strategic alignment among innovators, clinicians, and policymakers.

How converging technological advances, patient-centered care models, and diagnostics-driven pathways are reshaping clinical practice and commercial strategy in male infertility

The landscape of male infertility care is undergoing transformative shifts driven by technological maturation, changing patient expectations, and a convergence of diagnostics and therapeutics. Precision diagnostics, including more accessible genetic testing and high-resolution semen analysis, are redefining diagnostic pathways and enabling tailored interventions. Simultaneously, the refinement of assisted reproductive procedures, such as intracytoplasmic sperm injection and targeted sperm retrieval techniques, has expanded options for couples where male factor issues are prominent.

Concurrently, non-conventional pathways are gaining traction: lifestyle and alternative therapies such as acupuncture, nutritional optimization, and structured weight management are increasingly integrated into preconception care plans. These shifts reflect broader health system priorities that favor holistic, patient-centered models and preventive strategies. On the commercial side, device miniaturization, improvements in laboratory automation, and the adoption of digital tools for remote monitoring have lowered barriers to scaling services, prompting new entrants and strategic partnerships. Taken together, these dynamics are reshaping clinical decision-making and accelerating the translation of research into practice.

Evaluating the cumulative operational and supply chain consequences of United States tariffs introduced in 2025 on devices, diagnostics, and therapeutic distribution within reproductive health

The introduction and implementation of tariffs in the United States in 2025 have introduced measurable friction into global supply chains that support reproductive health technologies, affecting manufacturers, distributors, and clinical service providers. Increased import costs for specialized equipment such as centrifuges, incubators, and precision microscopes can raise procurement complexity for laboratories and clinics, encouraging some providers to reassess supplier relationships and inventory strategies. In response, manufacturers and distributors have explored options including local assembly, diversified sourcing, and pricing adjustments to preserve access to essential instrumentation.

Beyond devices, tariffs can influence the availability and cost structure of diagnostics consumables and reagents used in genetic testing, hormone assays, and semen analysis. Those pressures have incentivized laboratory networks to optimize procurement cycles, invest in technical validation for alternative suppliers, and accelerate adoption of more efficient workflows that reduce per-test consumable use. Meanwhile, biopharmaceuticals and supplements that cross borders face shifted economics that may affect distribution channel strategies, with some vendors prioritizing direct sales or regional partnerships to mitigate tariff exposure. As a result, stakeholders are balancing near-term operational responses with longer-term strategic moves to shore up resilience against ongoing trade policy volatility.

Segment-focused insights linking treatment modalities, product typologies, clinical end users, and distribution strategies to prioritize development and commercialization pathways

Segment-level dynamics in male infertility reveal differentiated value drivers that inform product development and go-to-market strategies across treatment modalities, product types, end users, and distribution pathways. Based on treatment type, the landscape spans assisted reproductive technology, lifestyle and alternative therapies, medical therapy, and surgical procedures; assisted reproductive technology itself encompasses ICSI, IUI, and IVF, while lifestyle and alternative therapies include acupuncture, nutritional supplementation, and weight management, medical therapy incorporates antibiotic therapy, antioxidant therapy, and hormonal therapy, and surgical procedures comprise testicular sperm extraction, varicocelectomy, and vasovasostomy. Each of these treatment areas presents distinct clinical workflows, reimbursement considerations, and evidence generation needs that influence adoption timelines.

Based on product type, innovation and commercialization strategies must address devices, diagnostics, drugs, and supplements; within devices, the focus includes centrifuges, incubators, and microscopes, diagnostics cover genetic testing, hormone level testing, and semen analysis, drugs consist of antibiotic, antioxidant, and hormone classes, and supplements traverse amino acids, herbal extracts, and vitamins. Product design, regulatory pathways, and lab integration requirements differ markedly between capital equipment and point-of-care diagnostics, creating varied barriers to entry and collaboration opportunities. Based on end user, the market is served by diagnostic centers, fertility clinics, hospitals, and research institutes, each with unique procurement cycles, clinical expertise, and data integration needs. Based on distribution channel, organizations deploy direct sales, hospital pharmacies, online pharmacies, and retail pharmacies, and channel strategy influences margin structures, access to prescribers, and patient reach. Together, these intersecting segmentation lenses highlight where clinical demand, regulatory clarity, and commercial feasibility align to create priority opportunities for investment and partnership.

Regional dynamics and regulatory complexities across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape adoption, manufacturing, and partnership strategies

Regional dynamics exert considerable influence on clinical practice standards, regulatory expectations, and commercial pathways for male infertility products and services. In the Americas, clinical adoption trends and reimbursement structures favor integrated fertility services that combine diagnostics with assisted reproductive technologies; this environment supports investments in advanced laboratory instrumentation and comprehensive clinic-level service models. Meanwhile, regulatory harmonization efforts in the region shape cross-border supplier strategies and create opportunities for suppliers that can demonstrate robust clinical and quality data.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable healthcare funding models create a mosaic of adoption rates and clinical practices. Some European markets emphasize stringent diagnostic protocols and outcome reporting, whereas certain markets in the Middle East and Africa prioritize rapid capacity development and public-private partnerships to expand access. Across these jurisdictions, local manufacturing capacity and collaborative training programs influence procurement decisions. In Asia-Pacific, demographic shifts, rising awareness of fertility health, and expanding private healthcare sectors drive demand for both high-throughput diagnostics and point-of-care solutions. Rapidly developing clinical infrastructure and strong domestic manufacturing ecosystems encourage regionally tailored product designs and strategic alliances that accelerate commercialization timelines.

Competitive landscape analysis revealing how incumbents, specialized innovators, and strategic partnerships are driving differentiation and clinical adoption in male infertility

Competitive activity in male infertility spans long-established medical device and diagnostics firms, niche biotechnology innovators, clinically focused service providers, and emerging digital health entrants. Incumbent device and diagnostics companies emphasize reliability, regulatory compliance, and integration with laboratory information systems, whereas newer entrants frequently focus on automation, cost-efficiency, and digital analytics to differentiate their offerings. Strategic partnerships between clinical networks and technology developers are increasingly common, enabling co-development of validation studies and real-world evidence that support market access and clinician adoption.

At the same time, companies that combine diagnostic capabilities with therapeutic or service offerings gain advantages in end-to-end solutions, driving consolidation in certain segments. Smaller specialized firms often target unmet clinical needs with focused technologies such as advanced sperm selection, non-invasive genetic assays, or minimally invasive retrieval tools, and they frequently rely on licensing or strategic distribution agreements with larger players to scale. Across the competitive landscape, investment in clinical evidence, regulatory strategy, and post-market surveillance remains central to sustaining differentiation and supporting long-term adoption among clinicians and patients.

Actionable recommendations for industry leaders to align clinical evidence, supply chain resilience, patient-centered services, and channel strategies for durable competitive advantage

Industry leaders must pursue prioritized actions that align clinical utility with commercial viability and supply chain resilience. First, strengthening evidence generation through targeted clinical studies and real-world data initiatives will accelerate clinician confidence in new diagnostics and therapeutics and enable clearer value communication to payers and procurement bodies. Second, diversifying supply chains and considering regional manufacturing or assembly partnerships can mitigate exposure to trade policy shifts and ensure continuity of access to critical devices and consumables. These operational moves should be paired with investments in quality systems and regulatory readiness to speed market entry.

Third, organizations should adopt patient-centered service models that integrate lifestyle interventions, diagnostic precision, and coordinated referral pathways between diagnostic centers, fertility clinics, hospitals, and research institutes. Fourth, channel strategies must adapt: leveraging direct sales for institutional accounts while optimizing online and pharmacy partnerships to broaden patient access will balance reach with margin considerations. Finally, cultivating strategic alliances-whether through co-development, licensing, or clinical collaborations-will accelerate innovation, reduce time to validation, and distribute commercialization risk across complementary capabilities.

A rigorous multi-source research methodology combining clinical validation, regulatory review, and stakeholder interviews to ensure robust insights into male infertility care and commercialization

This research synthesis applied a multi-source, evidence-based methodology combining peer-reviewed literature, regulatory documentation, clinical guidelines, and primary interviews with clinicians, laboratory directors, and industry executives. The approach prioritized triangulation of quantitative laboratory performance data with qualitative insights on clinical decision-making, procurement behavior, and regulatory interpretation. Validation steps included cross-referencing device specifications with regulatory approvals, and corroborating clinical workflows with practicing specialists across diagnostic centers, fertility clinics, hospitals, and academic research institutes.

In addition, product-level analysis incorporated technical assessments of devices such as centrifuges, incubators, and microscopes, and evaluated diagnostic modalities including genetic testing, hormone level testing, and semen analysis against accepted clinical performance metrics. For therapeutic and supplement categories, the methodology emphasized mechanistic plausibility and clinical trial evidence where available, while recognizing the variable regulatory pathways that differentiate drugs, supplements, and complementary therapies. The research also examined distribution channel dynamics through interviews with procurement managers and channel partners, enabling a practical view of adoption barriers and facilitators across direct sales, hospital pharmacies, online pharmacies, and retail pharmacies.

Concise conclusion synthesizing clinical progress, operational challenges, and strategic priorities to guide stakeholders in transforming male infertility care delivery and commercialization

Male infertility represents a complex, evolving domain where clinical innovation, diagnostics advancement, and shifting commercial dynamics intersect. Progress in genetic and endocrine testing, refinements in assisted reproductive techniques, and growing emphasis on integrated care pathways have improved diagnostic clarity and expanded therapeutic choices. At the same time, operational pressures such as supply chain disruptions and evolving trade policy underscore the importance of resilient procurement strategies and regionalized commercialization plans.

Looking ahead, organizations that prioritize evidence-based innovation, form strategic partnerships across the value chain, and adapt distribution strategies to local realities will be best positioned to translate scientific progress into improved patient outcomes. By focusing on the alignment of clinical utility, regulatory compliance, and pragmatic channel execution, stakeholders can navigate the complexities of the landscape and help ensure that advances in male infertility care reach clinicians and patients efficiently and equitably.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advances in gene therapy targeting Y-chromosome microdeletions for male fertility optimization
  • 5.2. Surge in research on oxidative stress biomarkers guiding personalized antioxidant therapies in male infertility management
  • 5.3. Growing utilization of AI-driven semen analysis platforms for enhanced diagnostic accuracy in andrology labs
  • 5.4. Expansion of telemedicine-based fertility counseling services addressing male reproductive health access gaps
  • 5.5. Developments in 3D testicular organoids as predictive models for novel drug screening in male fertility research
  • 5.6. Increasing investment in non-hormonal male contraceptives influencing research in testicular function modulation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Male Infertility Market, by Treatment Type

  • 8.1. Assisted Reproductive Technology
    • 8.1.1. ICSI
    • 8.1.2. IUI
    • 8.1.3. IVF
  • 8.2. Lifestyle And Alternative Therapies
    • 8.2.1. Acupuncture
    • 8.2.2. Nutritional Supplementation
    • 8.2.3. Weight Management
  • 8.3. Medical Therapy
    • 8.3.1. Antibiotic Therapy
    • 8.3.2. Antioxidant Therapy
    • 8.3.3. Hormonal Therapy
  • 8.4. Surgical Procedures
    • 8.4.1. Testicular Sperm Extraction
    • 8.4.2. Varicocelectomy
    • 8.4.3. Vasovasostomy

9. Male Infertility Market, by Product Type

  • 9.1. Devices
    • 9.1.1. Centrifuges
    • 9.1.2. Incubators
    • 9.1.3. Microscopes
  • 9.2. Diagnostics
    • 9.2.1. Genetic Testing
    • 9.2.2. Hormone Level Testing
    • 9.2.3. Semen Analysis
  • 9.3. Drugs
    • 9.3.1. Antibiotics
    • 9.3.2. Antioxidants
    • 9.3.3. Hormones
  • 9.4. Supplements
    • 9.4.1. Amino Acids
    • 9.4.2. Herbal Extracts
    • 9.4.3. Vitamins

10. Male Infertility Market, by End User

  • 10.1. Diagnostic Centers
  • 10.2. Fertility Clinics
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Male Infertility Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Male Infertility Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Male Infertility Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Male Infertility Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Ferring Arzneimittel AG
    • 15.3.2. Merck KGaA
    • 15.3.3. Bayer AG
    • 15.3.4. Sun Pharmaceutical Industries Ltd
    • 15.3.5. Endo International plc
    • 15.3.6. Roche Diagnostics International AG
    • 15.3.7. Thermo Fisher Scientific Inc
    • 15.3.8. Cook Medical LLC
    • 15.3.9. Hamilton Thorne Ltd
    • 15.3.10. Vitrolife AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL MALE INFERTILITY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MALE INFERTILITY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS MALE INFERTILITY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL MALE INFERTILITY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. MALE INFERTILITY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. MALE INFERTILITY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MALE INFERTILITY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MALE INFERTILITY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MALE INFERTILITY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MALE INFERTILITY MARKET SIZE, BY ICSI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MALE INFERTILITY MARKET SIZE, BY ICSI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MALE INFERTILITY MARKET SIZE, BY ICSI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MALE INFERTILITY MARKET SIZE, BY ICSI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MALE INFERTILITY MARKET SIZE, BY ICSI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MALE INFERTILITY MARKET SIZE, BY ICSI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MALE INFERTILITY MARKET SIZE, BY IUI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MALE INFERTILITY MARKET SIZE, BY IUI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MALE INFERTILITY MARKET SIZE, BY IUI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MALE INFERTILITY MARKET SIZE, BY IUI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MALE INFERTILITY MARKET SIZE, BY IUI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MALE INFERTILITY MARKET SIZE, BY IUI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MALE INFERTILITY MARKET SIZE, BY IVF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MALE INFERTILITY MARKET SIZE, BY IVF, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MALE INFERTILITY MARKET SIZE, BY IVF, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MALE INFERTILITY MARKET SIZE, BY IVF, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MALE INFERTILITY MARKET SIZE, BY IVF, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MALE INFERTILITY MARKET SIZE, BY IVF, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MALE INFERTILITY MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MALE INFERTILITY MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MALE INFERTILITY MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MALE INFERTILITY MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MALE INFERTILITY MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MALE INFERTILITY MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MALE INFERTILITY MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MALE INFERTILITY MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MALE INFERTILITY MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MALE INFERTILITY MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MALE INFERTILITY MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MALE INFERTILITY MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MALE INFERTILITY MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MALE INFERTILITY MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MALE INFERTILITY MARKET SIZE, BY WEIGHT MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MALE INFERTILITY MARKET SIZE, BY WEIGHT MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MALE INFERTILITY MARKET SIZE, BY WEIGHT MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MALE INFERTILITY MARKET SIZE, BY WEIGHT MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MALE INFERTILITY MARKET SIZE, BY TESTICULAR SPERM EXTRACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MALE INFERTILITY MARKET SIZE, BY TESTICULAR SPERM EXTRACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MALE INFERTILITY MARKET SIZE, BY TESTICULAR SPERM EXTRACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MALE INFERTILITY MARKET SIZE, BY TESTICULAR SPERM EXTRACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MALE INFERTILITY MARKET SIZE, BY TESTICULAR SPERM EXTRACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MALE INFERTILITY MARKET SIZE, BY TESTICULAR SPERM EXTRACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MALE INFERTILITY MARKET SIZE, BY VARICOCELECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MALE INFERTILITY MARKET SIZE, BY VARICOCELECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MALE INFERTILITY MARKET SIZE, BY VARICOCELECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MALE INFERTILITY MARKET SIZE, BY VARICOCELECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MALE INFERTILITY MARKET SIZE, BY VARICOCELECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MALE INFERTILITY MARKET SIZE, BY VARICOCELECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MALE INFERTILITY MARKET SIZE, BY VASOVASOSTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MALE INFERTILITY MARKET SIZE, BY VASOVASOSTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MALE INFERTILITY MARKET SIZE, BY VASOVASOSTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MALE INFERTILITY MARKET SIZE, BY VASOVASOSTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MALE INFERTILITY MARKET SIZE, BY VASOVASOSTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MALE INFERTILITY MARKET SIZE, BY VASOVASOSTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MALE INFERTILITY MARKET SIZE, BY CENTRIFUGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MALE INFERTILITY MARKET SIZE, BY CENTRIFUGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MALE INFERTILITY MARKET SIZE, BY CENTRIFUGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MALE INFERTILITY MARKET SIZE, BY CENTRIFUGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MALE INFERTILITY MARKET SIZE, BY CENTRIFUGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MALE INFERTILITY MARKET SIZE, BY CENTRIFUGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MALE INFERTILITY MARKET SIZE, BY INCUBATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MALE INFERTILITY MARKET SIZE, BY INCUBATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MALE INFERTILITY MARKET SIZE, BY INCUBATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MALE INFERTILITY MARKET SIZE, BY INCUBATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MALE INFERTILITY MARKET SIZE, BY INCUBATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MALE INFERTILITY MARKET SIZE, BY INCUBATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MALE INFERTILITY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MALE INFERTILITY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MALE INFERTILITY MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MALE INFERTILITY MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MALE INFERTILITY MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MALE INFERTILITY MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONE LEVEL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONE LEVEL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONE LEVEL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONE LEVEL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONE LEVEL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONE LEVEL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MALE INFERTILITY MARKET SIZE, BY SEMEN ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MALE INFERTILITY MARKET SIZE, BY SEMEN ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MALE INFERTILITY MARKET SIZE, BY SEMEN ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MALE INFERTILITY MARKET SIZE, BY SEMEN ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MALE INFERTILITY MARKET SIZE, BY SEMEN ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MALE INFERTILITY MARKET SIZE, BY SEMEN ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MALE INFERTILITY MARKET SIZE, BY AMINO ACIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MALE INFERTILITY MARKET SIZE, BY AMINO ACIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MALE INFERTILITY MARKET SIZE, BY AMINO ACIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MALE INFERTILITY MARKET SIZE, BY AMINO ACIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MALE INFERTILITY MARKET SIZE, BY AMINO ACIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MALE INFERTILITY MARKET SIZE, BY AMINO ACIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MALE INFERTILITY MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MALE INFERTILITY MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MALE INFERTILITY MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MALE INFERTILITY MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MALE INFERTILITY MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MALE INFERTILITY MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MALE INFERTILITY MARKET SIZE, BY VITAMINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MALE INFERTILITY MARKET SIZE, BY VITAMINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MALE INFERTILITY MARKET SIZE, BY VITAMINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MALE INFERTILITY MARKET SIZE, BY VITAMINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MALE INFERTILITY MARKET SIZE, BY VITAMINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MALE INFERTILITY MARKET SIZE, BY VITAMINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL MALE INFERTILITY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL MALE INFERTILITY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL MALE INFERTILITY MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL MALE INFERTILITY MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL MALE INFERTILITY MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL MALE INFERTILITY MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL MALE INFERTILITY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL MALE INFERTILITY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL MALE INFERTILITY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL MALE INFERTILITY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL MALE INFERTILITY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL MALE INFERTILITY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL MALE INFERTILITY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL MALE INFERTILITY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS MALE INFERTILITY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS MALE INFERTILITY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS MALE INFERTILITY MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS MALE INFERTILITY MARKET SIZE, BY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS MALE INFERTILITY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TEC